NASDAQ:MNKD MannKind (MNKD) Stock Forecast, Price & News $4.03 +0.02 (+0.50%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$4.01▼$4.1550-Day Range$4.01▼$5.4552-Week Range$2.91▼$5.75Volume2.74 million shsAverage Volume2.31 million shsMarket Capitalization$1.08 billionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MannKind MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside73.7% Upside$7.00 Price TargetShort InterestBearish14.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$171,218 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.07) to $0.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector783rd out of 963 stocksPharmaceutical Preparations Industry363rd out of 446 stocks 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, MannKind has a forecasted upside of 73.7% from its current price of $4.03.Amount of Analyst CoverageMannKind has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.58% of the outstanding shares of MannKind have been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in MannKind has recently increased by 6.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNKD. Previous Next 2.3 News and Social Media Coverage News SentimentMannKind has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MannKind this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $171,218.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.95% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow in the coming year, from ($0.07) to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -21.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -21.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About MannKind (NASDAQ:MNKD) StockMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Read More MNKD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNKD Stock News HeadlinesSeptember 7, 2023 | markets.businessinsider.com7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue GrowthSeptember 5, 2023 | finance.yahoo.comMannKind Corporation Announces Participation at Upcoming ConferencesSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 4, 2023 | thestreet.com3 Stocks the Market Loves to HateAugust 22, 2023 | finance.yahoo.comWhen Will MannKind Corporation (NASDAQ:MNKD) Breakeven?August 22, 2023 | finance.yahoo.com3 Biotech Stocks to Sell in August Before They Crash and BurnAugust 14, 2023 | msn.comHC Wainwright & Co. Maintains Mannkind (MNKD) Buy RecommendationAugust 9, 2023 | msn.comCantor Fitzgerald Maintains Mannkind (MNKD) Overweight RecommendationSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 8, 2023 | finance.yahoo.comWhy MannKind Stock Soared 19% Higher on TuesdayAugust 8, 2023 | finance.yahoo.comQ2 2023 MannKind Corp Earnings CallAugust 8, 2023 | seekingalpha.comMannKind's Robust Patient Demand, Operational Efficiency To Drive Revenue Beyond Q2 2023August 8, 2023 | washingtonpost.comMannKind: Q2 Earnings SnapshotAugust 8, 2023 | markets.businessinsider.comMannKind Corp. Q2 Earnings SummaryAugust 8, 2023 | finance.yahoo.comMannKind Corporation Reports 2023 Second Quarter Financial ResultsAugust 8, 2023 | finance.yahoo.comHere's What Key Metrics Tell Us About MannKind (MNKD) Q2 EarningsAugust 8, 2023 | finance.yahoo.comMannKind (MNKD) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | seekingalpha.comMannKind Corporation 2023 Q2 - Results - Earnings Call PresentationAugust 6, 2023 | finance.yahoo.comMNKD Aug 2023 4.500 putAugust 4, 2023 | benzinga.comEarnings Preview For MannKindAugust 1, 2023 | finance.yahoo.comMannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare ConferenceJuly 31, 2023 | finance.yahoo.comMannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023July 26, 2023 | seekingalpha.comMannKind: Impressive Progress, But In Need Of Strengthened FinancesJuly 23, 2023 | thestreet.comMannKind Relies on 'Death Spiral' Financing to Help Settle Looming DebtJuly 21, 2023 | finance.yahoo.comWhy These 3 Stocks Are the Worst Ways to Play Biotech Right NowJuly 10, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Hold Rating for MannKind (MNKD)July 5, 2023 | gurufocus.comInsider Sell: MannKind Corp CEO Michael Castagna Sells 10,000 SharesSee More Headlines Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Company Calendar Last Earnings8/07/2023Today9/27/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees391Year Founded1991Price Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.50 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+73.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,400,000.00 Net Margins-30.00% Pretax Margin-30.00% Return on EquityN/A Return on Assets-16.03% Debt Debt-to-Equity RatioN/A Current Ratio2.37 Quick Ratio2.11 Sales & Book Value Annual Sales$99.77 million Price / Sales10.84 Cash FlowN/A Price / Cash FlowN/A Book Value($0.95) per share Price / Book-4.24Miscellaneous Outstanding Shares268,360,000Free Float257,621,000Market Cap$1.08 billion OptionableOptionable Beta1.58 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Michael E. Castagna Pharm.D. (Age 46)CEO & Director Comp: $1.26MMr. Steven B. Binder (Age 60)Chief Financial Officer Comp: $800.2kDr. David B. Thomson (Age 56)Exec. VP, Gen. Counsel & Sec. Comp: $798.53kDr. Stuart A. Tross Ph.D. (Age 56)Exec. VP and Chief People & Workplace Officer Comp: $678.4kMr. Sanjay Singh M.B.A. (Age 56)Exec. VP of Technical Operations Comp: $364.53kMs. Lauren M. Sabella (Age 62)Exec. VP & COO Mr. Thomas Hofmann M.D.Ph.D., Sr. VP & Chief Scientific OfficerMs. Rosabel Realica Alinaya (Age 62)VP of Investor Relations & Treasury Mr. John F. Bedard (Age 73)Sr. VP of Worldwide Regulatory Affairs Mr. James Patrick McCauley Jr. (Age 57)J.D., M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDGeronNASDAQ:GERNOPKO HealthNASDAQ:OPKInnovivaNASDAQ:INVAIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsDavidson Kempner Capital Management LPBought 2,500,000 shares on 9/12/2023Ownership: 0.000%Michael CastagnaSold 10,000 sharesTotal: $46,100.00 ($4.61/share)David ThomsonSold 8,100 sharesTotal: $38,718.00 ($4.78/share)Wolverine Trading LLCSold 18,800 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemBought 3,660 shares on 8/21/2023Ownership: 0.118%View All Insider TransactionsView All Institutional Transactions MNKD Stock - Frequently Asked Questions Should I buy or sell MannKind stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares. View MNKD analyst ratings or view top-rated stocks. What is MannKind's stock price forecast for 2023? 3 analysts have issued 12-month price targets for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $7.50. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 73.7% from the stock's current price. View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts. How have MNKD shares performed in 2023? MannKind's stock was trading at $5.27 at the beginning of 2023. Since then, MNKD stock has decreased by 23.5% and is now trading at $4.03. View the best growth stocks for 2023 here. When is MannKind's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our MNKD earnings forecast. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) posted its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.04. The biopharmaceutical company had revenue of $48.61 million for the quarter, compared to analysts' expectations of $42.03 million. What ETFs hold MannKind's stock? ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD). What is MannKind's stock symbol? MannKind trades on the NASDAQ under the ticker symbol "MNKD." Who are MannKind's major shareholders? MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.67%), State Street Corp (5.71%), Davidson Kempner Capital Management LP (0.00%), Geode Capital Management LLC (1.99%), Northern Trust Corp (0.94%) and Charles Schwab Investment Management Inc. (0.74%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MannKind's stock price today? One share of MNKD stock can currently be purchased for approximately $4.03. How much money does MannKind make? MannKind (NASDAQ:MNKD) has a market capitalization of $1.08 billion and generates $99.77 million in revenue each year. The biopharmaceutical company earns $-87,400,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. How many employees does MannKind have? The company employs 391 workers across the globe. How can I contact MannKind? MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081. This page (NASDAQ:MNKD) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.